Insulet Corp
PODD: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$521.00 | Ppsgwwj | Cfhydynyj |
Insulet Poised for Boost From U.S. Launch of Omnipod 5
Business Strategy and Outlook
With little direct competition in patch pumps, Insulet has been able to convert more users to its innovative, tubeless insulin pump. We expect meaningful profitability gains over the next five years.